To investigate the mechanisms of colorectal carcinogenesis, we searched for genes regulated by adenomatous polyposis coli gene product (APC) and identified a novel gene, termed HELAD1 (helicase, APC down-regulated 1). A recombinant polypeptide representing the ATPases associated with cellular activities (AAA) domain of the HELAD1 product showed 3' to 5' helicase activity and exonuclease activity in vitro. HELAD1 was abundantly expressed in 16 of 20 colon cancers examined but hardly detectable in corresponding non-cancerous mucosae. Treatment of colon-cancer cells with antisense oligonucleotides suppressed its expression and induced apoptosis. These data revealed an importance of HELAD1 in colorectal carcinogenesis and suggest that suppression of HELAD1 may be a promising therapeutic strategy.
Introduction
Mutations in the APC gene are responsible for familial adenomatous polyposis coli as well as for sporadic colorectal tumors Kinzler et al., 1991) ; its normal product functions as a tumor suppressor. In association with b-catenin, wild-type APC acts as a negative regulator of the Wnt/wingless signaling pathway by modulating cytoplasmic and nuclear levels of b-catenin (Munemitsu et al., 1995) . Along with a scaffold protein, Axin/Conductin, APC facilitates the phosphorylation of b-catenin by glycogen synthase kinase 3b (GSK-3b), leading to degradation of b-catenin via the ubiquitin -proteosome pathway (Behrens et al., 1998; Hamada et al., 1999; Hart et al., 1999; Nakamura et al., 1998) . Abnormal accumulation of b-catenin as a consequence of mutations in the APC, b-catenin or Axin/Conductin genes has been observed in a variety of human cancers including colorectal and hepatocellular carcinomas Miyoshi et al., 1998; Satoh et al., 2000) . When translocated into the nucleus, b-catenin interacts with T-cell factor/lymphocyte enhancer factor (Tcf/LEF) Morin et al., 1997) to activate transcription of downstream genes such as c-Myc (He et al., 1998), cyclinD1 (Tetsu and McCormick, 1999; Shtutman et al., 1999) , c-jun, fra-1 (Mann et al., 1999) , MMP7 (Brabletz et al., 1999; Crawford et al., 1999) , PPARd (He et al., 1999) , NBL4 , WISP1 (Xu et al., 2000) , MDR1 (Yamada et al., 2000) , AF17 (Lin et al., 2001 ) and ENC1 .
Evidence is compelling that DNA helicases play crucial roles in biological processes including DNA replication, DNA repair, and transcription. A common mechanism for controlling initiation of eukaryotic DNA replication, for example, involves minichromosome maintenance protein complex (MCM), which contains helicase activity. Together with DNA polymerases, the MCM complex unwinds duplex DNA at replication origins (Eisen and Lucchesi, 1998; Takisawa et al., 2000) . XPB and XPD, helicases responsible for nucleotide excision repair, form a complex with TFIIH and play a role in transcription as well as DNA repair (Guzder et al., 1994a,b) . Consistent with their essential biological roles, inactivation of helicases has been implicated in human genetic disorders such as xeroderma pigmentosum (Weeda et al., 1990) , trichothiodystrophy (Broughton et al., 1994) , Bloom syndrome (Ellis et al., 1995) , Werner syndrome (Yu et al., 1996) , and Rothmund Thomson syndrome (Kitao et al., 1999) . On the other hand, over-expression of rck/ p54, a protein belonging to the DEAD box protein/ RNA family of helicases, is seen in B-cell lymphomas with t(11 ; 14)(q23 ; q32), and also in 50% of colorectal adenocarcinomas (Seto et al., 1995; Nakagawa et al., 1999) . In addition, the DEAD box gene DDX1, encoding a putative RNA helicase, is co-amplified with N-myc in some retinoblastomas and neuroblastomas (Godbout et al., 1998) . The precise roles of enhanced helicases in human carcinogenesis remain to be resolved.
In this study we describe isolation and characterization of a novel human gene, HELAD1, encoding a protein with helicase activity, and document its involvement in colorectal carcinogenesis.
Results
Detection of a novel gene with reduced expression in response to transduction of APC We previously reported reduced expression of b-catenin and a decrease in Tcf/LEF-specific transcriptional activity when SW480 cells expressing mutant APC and wild-type b-catenin were infected with Ad-Axin or Ad-APC, a construct that expresses the 20-amino-acid repeat domain of APC . When we compared expression profiles between SW480 cells infected with either Ad -APC or Ad -LacZ by means of cDNA microarrays containing 23040 independent target cDNAs, we found that a gene corresponding to Unigene accession number Hs.23467 showed significantly decreased expression in response to APC. Subsequent RT -PCR experiments confirmed that Ad -APC, but not Ad -Axin or Ad -LacZ, decreased expression of this gene in SW480 cells (Figure 1a) . Expression of the novel gene was also down-regulated when we infected other colon-cancer cell lines, including SNUC2A and LoVo, with Ad -APC (data not shown). We named the gene HELAD1 (Helicase, adenomatous polyposis coli down-regulated 1), in view of characteristics revealed in the experiments described below.
Expression of HELAD1 in colon-cancer tissues
Since accumulation of b-catenin as a result of mutations in either APC or b-catenin is a frequent feature of colorectal tumors, we examined expression of HELAD1 in human colon-cancer tissues and corresponding non-cancerous mucosae by semi-quantitative RT -PCR, and found increased expression in 16 (80%) of the 20 tumors examined (Figure 1b ). In the four other cases, expression levels were similar to those in corresponding normal tissues. This result was in line with a view that HELAD1 is up-regulated in response to activation of the b-catenin/Tcf transcriptional complex.
Expression of HELAD1 in human tissues
Northern-blot analysis using an RT -PCR product of HELAD1 as a probe detected an 11-kb transcript in human fetal brain and lung, and a 7.5-kb transcript in fetal kidney and liver (Figure 1c) . However, these transcripts were undetectable in any adult human tissues examined.
Since the UniGene clone (Hs.23467) was smaller than the transcripts we detected by Northern analysis, we screened a human fetal brain cDNA library and carried out 5' RACE experiments. This effort identified two HELAD1 transcripts with different 5' sequences (GenBank with accession numbers AB063115 and AB063116). A homology search with its deduced amino acid sequence using BLAST program in NCBI indicated 28% identity with unc-53 in C. elegans.
Comparison of HELAD1 cDNA sequences with genomic sequences in NCBI using the BLAST program revealed that HELAD1 consisted of 38 exons and belonged in chromosomal band 11p15.1. A search for protein motifs with the Simple Modular Architecture 
Subcellular localization of HELAD1 protein
To investigate the location of HELAD1 protein within mammalian cells, we transiently transfected a plasmid expressing Flag-tagged HELAD1 protein (pFLAG-HELAD1) into COS7 cells and observed the tagged protein by immunocytochemical staining. HELAD1 protein was detected with an anti-Flag antibody on Western blots (Figure 2a ), and subsequent microscopic analysis indicated a primarily cytoplasmic and nuclear localization ( Figure 2b ). We also separated nuclei from the cells and carried out Western blotting analysis with anti-Flag antibody and identified its expression in the nucleus ( Figure  2c ).
DNA helicase activity
Since the AAA domain is observed in a number of proteins encoding DEAD/DEAH box helicase, as well as ABC transporters, and the A and B motifs of the Walker-type NTP binding domain are commonly observed in helicases, we examined the helicase activity of the HELAD1 protein. We prepared a recombinant GST-fusion protein containing the AAA domain of HELAD1 (GST -HELAD1). Partiallyduplex DNA substrates were mixed with GST -HELAD1 or with recombinant protein of Werner helicase (WRN) in the presence of ATP ( Figure 3a ). Substrates were unwound by GST -HELAD1 or WRN, and the oligonucleotides were smaller in size compared to the original (18mer), indicating nuclease as well as helicase activities of HELAD1 and WRN. Further examination revealed that the helicase activity of recombinant GST -HELAD1 protein was in the 3' to 5' direction ( Figure 3a ) and was very weakly in the 5' to 3' (Figure 3b ).
Induction of apoptosis by anti-sense S-oligonucleotides of HELAD1
To examine the effect of this gene on cell growth, we synthesized anti-sense (AS2 and AS3) and control (SE2 and SE3) S-oligonucleotides corresponding to DNA sequences around the first ATG. Almost all SW480 cells incorporated transfected FITC-labeled S-oligonucleotides into their nuclei (data not shown). The antisense, but not the sense, S-oligonucleotides significantly suppressed expression of HELAD1 within 24 h after transfection (Figure 4a ). The numbers of viable cells transfected with antisense S-oligonucleotides (AS2=0.32+0.02, AS3=0.31+0.08) were significantly decreased after transfection, compared with those transfected with control S-oligonucleotides (SE2=0.69+0.07, SE3=0.84+0.05) (Figure 4b ). FACS analysis detected a larger proportion of sub- 
Discussion
We isolated from cDNA microarrays a novel gene, HELAD1, which encodes a protein containing a CH domain at the amino-terminus and a consensus motif of AAA (ATPases associated with various cellular activities) at the carboxy-terminus, and demonstrated helicase and endonuclease activities of its product in vitro.
The CH domains have been assumed to confer an actin-binding to a variety of cytoskeletal and signalling molecules (Castresana and Saraste, 1995) . Proteins containing the CH domain are categorized into three groups: (1) the fimbrin family of monometric actincross linking molecules which contain two actinbinding domains; (2) diametric cross linking proteins and monometric F-actin binding proteins each of which contains one actin-binding domain, and (3) proteins containing a single amino-terminal CH domain (Stradal et al., 1998) . According to the categorization indicated above, HELAD1 is classified into the third group that includes calponin, a molecule involved in contraction of smooth muscle, IQGAP, a signaling molecule, and the proto-oncogene Vav. HELAD1 is the first example that contains both CH and helicase domains, suggesting that proteins having the CH domain may exert a wide range of biological function.
Proteins of the AAA family were first categorized as having one or two copies of a well-conserved cassette of 230 -250 amino acids encompassing Walker A and B motifs (Neuwald et al., 1999) . The AAA family includes regulatory components of proteases, proteasomal subunits, peroxisomal biogenesis proteins, Mg 2+ and CO 2+ chelatases, vesicle synthesis protein, dynein motor protein, and proteins involved in DNA replication, recombination, restriction, and transcription as well as sporulation in bacteria (Patel and Latterich, 1998; Neuwald et al., 1999) . Among them RuvBL1, a helicase homologous to RuvB of E. coli, plays important roles in the late stages of homologous genetic recombination and the recombinational repair of damaged DNA (Kanemaki et al., 1999) . MCM proteins, which also contain AAA domains, are components of pre-replicative complexes and essential for initiating DNA replication in eukaryotes (Takisawa et al., 2000; Tye and Sawyer, 2000) . MCM proteins are down-regulated in cells that are undergoing differentiation or quiescence, and are more abundantly expressed in dysplastic or malignant tissues than in normal tissues (Freeman et al., 1999) . Thus, dysplastic cells may be characterized in functional terms as remaining in the cell cycle and/or accelerated DNA replication due to deregulation of normal controls over cellular proliferation. Since expression of HELAD1 is also enhanced in colorectal cancers, it may be involved in cell cycle progression and/or DNA replication. In addition, proteins containing the AAA consensus motif often possess chaperone-like functions that assist in the assembly, operation, or disassembly of protein complexes (Neuwald et al., 1999) and the hexametric architecture of helicases can provide a hole through which DNA or RNA can be threaded and assembled into DNA-protein complexes (Tye and Sawyer, 2000; Patel and Picha, 2000) ; hence HELAD1 may be able to interact with itself or other proteins. Future identification of its binding partner(s) will help us to better understand the physiological roles of this enzyme.
In our experiments HELAD1 protein revealed both helicase and exonuclease activities in a fashion similar to WRN, a protein that is more highly expressed in transformed cells and tumor cells than in normal cells (Shiratori et al., 1999) . We examined expression of the WRN and BLM genes and found that both were expressed more abundantly in seven of 12 colorectal cancers examined than in corresponding normal tissues (data not shown). Those results suggested that coloncancer cells might require high expression of helicases in order to survive. However, the distribution of HELAD1 expression levels among normal human tissues was quite different from WRN; e.g. WRN is expressed abundantly in pancreas and placenta, and moderately in heart and skeletal muscle (Yu et al., 1996) , but expression of HELAD1 was hardly detectable in any of the adult tissues we examined although it was abundant in fetal tissues. Interestingly, HELAD1 shares 28% identity with unc-53 in C. elegans, overexpression of which leads to extension of growth cones along the a -p axis (Hedgecock et al., 1987; Hekimi and Kershaw, 1993) . Furthermore, in experiments reported here, expression of HELAD1 in cancer cells was downregulated by transduction of APC, whose product is essential for control of axis formation, cellular motility and differentiation (Bienz and Clevers, 2000) . These data strongly suggest that expression of HELAD1 is likely to have a role in morphogenesis and/or differentiation. Although we have not proven that HELAD1 is a direct target of the transcriptional complex of Tcf/ LEF, activated HELAD1 may facilitate the transcription of the target genes.
Our evidence that the great majority of colorectal cancers express HELAD1 abundantly, and that wildtype APC can reduce its amount in such tumors, strongly support the view that inappropriate expression of this gene is a significant contributor to colorectal carcinogenesis. Notably, HELAD1 is absent in normal colon and other adult tissues, and suppression of HELAD1 in cancer cells by antisense S-oligonucleotides inhibited growth of cancer cells and induced cell death. Although the precise molecular mechanism by which the antisense S-oligonucleotides can suppress growth needs to be clarified, our data clearly indicate that HELAD1 should be a good candidate as a molecular marker as well as a molecular target for development of an effective therapeutic reagent for patients with colorectal tumors.
Materials and methods

Cell lines and tissue samples
Monkey fibroblasts (COS7), and human colon-cancer cell lines (SW480, SNU-C2A and LoVo) were obtained from the Isolation of a novel human helicase gene, HELAD1 H Ishiguro et al American Type Culture Collection (ATCC, Rockville, MD, USA). Human embryonic kidney cell line HEK293 was purchased from TaKaRa (Tokyo, Japan). All cell lines were grown as monolayers in appropriate media, and maintained at 378C in a humidified atmosphere with 5% CO 2 (for COS7, HEK293, SNU-C2A and LoVo) or without CO 2 (for SW480). Cancerous and corresponding non-cancerous tissues were obtained with informed consent from 20 patients who underwent colectomy.
Construction of recombinant adenovirus and transfection
Construction and preparation of adenoviruses expressing wild-type AXIN1, LacZ or the 20-amino-acid repeat domain of APC were carried out as described previously . SW480 cells growing in monolayers were infected by the viral solutions at MOIs of 100 and incubated at 378C for 1 h with brief agitation every 15 min, followed by addition of fresh medium. The transfected cells were maintained in an incubator for 72 h.
cDNA microarray
Fabrication of the cDNA-microarray slides has been described elsewhere (Ono et al., 2000) . For each analysis of expression profiles we prepared two sets of slides containing duplicate sets of 23040 cDNA spots, to reduce experimental fluctuation. Total RNAs were extracted from SW480 cells 72 h after infection with adenovirus constructs expressing either wild-type APC (Ad -APC) or LacZ (Ad -LacZ); T7-based RNA amplification was carried out using polyA RNA purified from the extracts, as described elsewhere (Ono et al., 2000) . Aliquots (2.5-mg) of amplified RNA (aRNA) from SW480 cells containing Ad -APC or Ad -LacZ were labeled respectively with Cy5 -dCTP or Cy3 -dCTP (Amersham Pharmacia Biotech). Hybridization, washing, and detection were carried out as described previously (Ono et al., 2000) . Genes were excluded from further investigation when the intensities of both Cy3 and Cy5 were below 100 000 fluorescence units; of the remainder, we selected those with Cy3/Cy5 signal ratios 42.0 for further investigation.
Isolation and sequencing of human HELAD1 cDNA
Among the genes that showed Cy3/Cy5 signal ratios 42.0, we focused on a gene with an in-house identification of A8247, since its expression was frequently elevated in coloncancer tissues. A search of databases in NCBI (National Center for Biotechnology Information) using the BLAST program identified homology with a 6.2-kb clustered nucleotide sequence (Unigene accession number Hs.23467). Since this sequence truncated the 5' region of the cDNA, we screened a human fetal brain cDNA library (Stratagene) with a PCR product amplified with primers corresponding to HELAD1 (5-AGAGACAGAAGAGACTGGAGCAA-3' and 5'-CCTAAGGTTCCCTGTGTCGTAG-3') and isolated a positive clone of approximately 9.0 kb. We determined the sequence of its 5' end by performing 5' rapid amplification of cDNA ends (5'RACE) using a Marathon cDNA amplification kit (Clontech). The cDNA template was synthesized from human fetal brain mRNA for amplification and the PCR was carried out using a gene-specific reverse primer (5'-GTATCGGGAGAGAGGCTGAAGAAGAGG-3') and the AP1 primer supplied in the kit. The nucleotide sequences were determined with an ABI PRISM 3700 DNA sequencer (PE Applied Biosystems) according to the manufacturer's instructions.
Northern-blot analysis
Human multiple-tissue blots (Clontech) were hybridized with the HELAD1 PCR product labeled by random-oligonucleotide priming with a Mega Label kit (Amersham Pharmacia Biotech). Pre-hybridization, hybridization and washing were performed according to the supplier's recommendations. The blots were autoradiographed with intensifying screens at 7808C for 48 h.
Extraction of RNA and RT -PCR
Total RNA was extracted from cell lines or tissues with TRIZOL reagent (Life Technologies) according to the manufacturer's instructions. Extracted RNA was treated with DNasel (Boehringer Mannheim) and reversely transcribed for single-stranded cDNA using oligo(dT) 12 -18 primer with Superscript II reverse transcriptase (GIBCO -BRL). Each single-stranded cDNA was diluted for subsequent PCR amplification by monitoring the glyceraldehyde-3-phosphate dehydrogenase gene (GAPDH) as a quantitative control. The primer sets for amplification were GAPDHF (5'-ACAA-CAGCCTCAAGATCATCAG-3') and GAPDHR (5'-GGTCCACCACTGACACGTTG-3') for GAPDH, and HELAD1F
(5'-GAATTGCGCCAGTACCTGTCCAA-3'), HELAD1R (5'-GTCATCGTGATGGGTGTTGCTGTT-3') for HELAD1. Each PCR reaction was carried out in 25 ml of 16 PCR buffer (TAKARA) for 5 min at 948C for initial denaturing, followed by 20 (for GAPDH) or 32 (for HELAD1) cycles of 948C for 30 s, 588C for 30 s and 728C for 30 s, in the GeneAmp PCR system 9700 (PE Applied Biosystems).
Immunocytochemical staining
To achieve flag-tagged HELAD1, we cloned the entire coding sequence into the appropriate site of pCMV -FLAG5a plasmid vector (Sigma) and transfected the plasmid clone, pFLAG -HELAD1, into COS7 cells. The transiently transfected COS7 cells were fixed with PBS containing 4% paraformaldehyde, then rendered permeable with PBS containing 0.1% Triton X-100 for 3 min at 48C. The cells were covered with blocking solution (2% BSA in PBS) for 30 min at room temperature to block nonspecific antibodybinding sites. Then the cells were incubated with a mouse anti-Flag antibody (Sigma). Antibodies were stained with a goat anti-mouse secondary antibody conjugated to rhodamine, and viewed with an ECLIPSE E800 microscope (Nikon). To confirm the expression of flag-tagged HELAD1 protein in transfected cells, we also performed Western blotting with either whole cell extract or nuclear extract using anti-Flag antibody (Sigma), in a manner described previously . Nuclei from the cells were separated as described previously (Chauveau et al., 1956) .
Preparation of recombinant protein representing the AAA domain of HELAD1 A recombinant protein of the AAA domain of HELAD1 fused with Glutathione S Transferase was prepared by cloning an RT -PCR product corresponding to codons 1958 -2234 of HELAD1 into the appropriate site of a plasmid vector (pGEX-5X; Amersham Pharmacia Biotech). Bacteria harboring pGEX -HELAD1 were grown in 1X LB media overnight and subsequently cultured in fresh media for an additional 3 h, followed by incubation with 0.5 mM isopropyl-beta-D-thiogalactoside (IPTG) for 4 h at 378C.
The bacteria were pelleted and sonicated in lysis buffer (1% Triton-X and 1 mM PMSF in PBS). The recombinant fusion protein was purified from the supernatant with Glutathione Sepharose beads (Amersham Pharmacia Biotech).
Helicase assay
Helicase activity was measured by displacing a radiolabeled DNA fragment from duplex -DNA substrates, as described elsewhere (Suzuki et al., 1997) . Each substrate DNA complex, consisting of oligonucleotide DR45 and a 32 P-labeled oligonucleotide (DR1735 or DR1753), was prepared by annealing the two components in 20 mM Tris -HCl (pH 7.5), 10 mM MgCl 2 , 100 mM NaCl, and 1 mM DTT. The substrate to determine 3' to 5' helicase activity was prepared by annealing DR45 (5'-TCGCGGAA GCTTGGC-TGCAGAATATTGCTAGCGGGAATTCGGCGCG-3') and DR1735 (5'-GCAGCCAAGCTTCCGCG-3'); the substrate for 5' to 3' was prepared by annealing DR45 and DR1753 (5'-CGCGCCGAATTCCCGCT-3'). Unhybridized oligonucleotides were removed using SUPREC02 according to the supplier's protocol (TaKaRa). Each DNA substrate (*2.5 pg) was incubated with 1 mg of GST-HELAD1 protein or recombinant WRN protein in a 20-ml reaction mixture containing 50 mM Tris-HCl buffer (pH 7.5), 1 mM MgCl 2 , 0.5 mg/ml BSA and 2 mM 2-mercaptoethanol at 378C for 60 min. Recombinant WRN-protein was kindly provided by Dr Furuichi (AGENE).
Suppression of HELAD1 by anti-sense S-oligonucleotides
HPLC-purified anti-sense oligonucleotide phosphorothioates HELAD1 -AS2 (5'-CAGAAACCGATTCCAT-3'), HEL-AD1 -AS3 (5'-GACTCAGAAACCGATT-3'), and FITClabeled-AS2 (5'-CAGAAACCGATTCCAT-3'), each designed to suppress the expression of HELAD1, and control oligonucleotide phosphorothioates HELAD1 -SE2 (5'-ATGGAATCGGTTTCTG-3') and HELAD1-SE3 (5'-AATCGGTTTCTGAGTC-3') were prepared. 1 mM of each oligonucleotide phosphorothioate was transfected into SW480 cells using Lipofectin reagent (GIBCO -BRL) according to the supplier's protocol. The efficiencies of transfection were the same for all oligonucleotides (data not shown). The cells were maintained for 5 days at 378C, then stained with Giemsa's solution (MERCK). To confirm suppression of HELAD1, semi-quantitative RT -PCR was carried out using as templates RNAs extracted from the cells 24 h after transfection.
MTT assay SW480 cells (1610 5 ) on 10-cm plates were transfected with antisense oligonucleotides or control oligonucleotides using Lipofectin reagent (GIBCO -BRL) according to the supplier's protocol. Viability of cells was evaluated by MTT assay 7 days after the treatment. MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (Sigma) was added to each dish at a concentration of 500 mg/ml, and plates were incubated at 378C for an additional 4 h; then acid-SDS (0.01N HCl/10%SDS) was added to all wells and mixed vigorously. After the plates were incubated overnight at 378C to dissolve the dark blue crystals, absorbance was measured at 570 nm with a Microplate Reader 550 (BIO-RAD).
Flow cytometry and TUNEL assay SW480 cells (5610 5 per 10-cm dish) were tranfected with 1 mM of each oligonucleotide phosphorothioate using Lipofectin reagent (GIBCO -BRL). The cells were trypsinized and collected at day 7, and cell suspensions were prepared using the Cycle Test plus (Becton Dickinson) according to the manufacturer's protocol. Flow-cytometric analyses were performed on a FACSCalibur (Becton Dickinson). The numbers of nuclei in G0 -G1, S, and G2 -M phases of the cell cycle, and the sub-G1 population, were determined from at least 20 000 ungated cells. Apoptotic cells were detected by TUNEL assay using an ApopTaq-kit (Intergen) according to the manufacturer's protocol.
Statistical analysis
Statistical significance was analysed by ANOVA with Scheffe's test, using commercially available software (Statview, Berkeley).
